GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Small and Large Bowel/Bedside Ultrasound Outperforms Abdominal X-Ray in Neonatal Necrotizing Enterocolitis: Frontiers in Pediatrics | July 2026
9

Bedside Ultrasound Outperforms Abdominal X-Ray in Neonatal Necrotizing Enterocolitis: Frontiers in Pediatrics | July 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated July 1, 2026

Introduction:

Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal radiography (AXR) in predicting the need for surgery.

Why was this study needed?

Abdominal radiography has traditionally been the first-line imaging modality for NEC, but it has limited sensitivity in detecting bowel ischemia and perforation. Bedside ultrasound may provide additional information to improve surgical decision-making.

What did the study show?

  • The study included 509 neonates with NEC, including 88 who required surgery.
  • Bedside ultrasound predicted the need for surgery significantly better than abdominal radiography.
  • Combining ultrasound with radiography further improved classification of patients at borderline risk.
  • Complex peritoneal fluid was the strongest ultrasound predictor of surgical intervention.
  • All imaging models demonstrated good calibration, supporting their clinical reliability.
  • Ultrasound provided valuable real-time assessment of bowel viability and intra-abdominal complications beyond conventional X-ray findings.

Clinical Impact:

Bedside abdominal ultrasound should be incorporated into the routine assessment of neonates with NEC, particularly when the need for surgery is uncertain. Combining ultrasound with radiography can improve risk stratification and facilitate earlier surgical consultation.

Take-Home Message:

Bedside abdominal ultrasound is superior to abdominal radiography in identifying neonates with NEC who require surgery. Used alongside conventional X-rays, it enhances clinical decision-making and may enable more timely surgical intervention.

Related Q&A

10

Common Drugs and Clostridioides difficile Infection: Gut | July 2026

Introduction: Antibiotic exposure is the best-established risk factor for Clostridioides difficile infection (CDI). However, the contribution of many commonly prescribed non-antibiotic medications has remained uncertain. This large Swedish...

11

Seated Anorectal Manometry Better Predicts Balloon Expulsion Success: AJG |June 2026

Dyssynergic defecation is commonly evaluated using anorectal manometry, traditionally performed in the left lateral decubitus position. However, defecation normally occurs in the seated position, raising questions about whether...

12

DOTATATE PET in Poorly Differentiated Extrapulmonary NEC: JNM | June 2026

Somatostatin receptor (SSTR) imaging with ⁶⁸Ga-DOTATATE PET is a cornerstone for well-differentiated neuroendocrine tumors, but its role in poorly differentiated neuroendocrine carcinoma (NEC) has remained uncertain. Previous retrospective...

13

F. prausnitzii Counters CRC Progression : Gastroenterology | Jun 2026

Introduction: The gut microbiome plays a central role in colorectal cancer (CRC) development, influencing inflammation, metabolism, immune responses, and tumor behavior. While several microbial species have been implicated...

14

Retatrutide in Type 2 Diabetes: Triple Agonist Delivers Powerful HbA1c and Weight Reduction: The Lancet | June 2026

Retatrutide is a once-weekly injectable triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. TRANSCEND-T2D-1 evaluated retatrutide as monotherapy in adults with type 2 diabetes inadequately controlled...

15

MLCK1 Targeting Separates ICI Colitis from Antitumor Immunity : Gut | May 2026

Introduction Immune Checkpoint Inhibitors have transformed cancer treatment across multiple malignancies, but immune-related adverse events remain major limitations to durable therapy. Among these toxicities, Immune Checkpoint Inhibitor Colitis...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer